Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Endocrinology

Ongoing Care, Monitoring, and Support

At a Glance

Ongoing care for metastatic PitNET (pituitary carcinoma) is individualized: teams use tailored MRI and hormone testing to watch for activity, interpret prognosis based on disease and treatment response, and provide supportive care for symptoms, anxiety, and quality of life.

Living with a diagnosis of Metastatic PitNET (pituitary carcinoma) means entering a phase of care focused on long-term management and vigilant monitoring. Because this condition often develops years after an initial pituitary tumor, navigating ongoing care requires balancing a commitment to regular testing with the emotional challenges of a chronic illness [1][2].

Long-Term Monitoring and Surveillance

There is no single “one-size-fits-all” schedule for monitoring a metastatic PitNET. Instead, your care team will create a clearly individualized surveillance framework based on known metastatic sites, your symptoms, tumor receptor expression, and your team’s protocol [3][1].

Imaging Protocols

  • Targeted Imaging: Contrast-enhanced MRI is a primary tool for monitoring [3]. Imaging should be tailored. While the central nervous system is a common site of spread, a full brain-and-spine MRI is not automatically required at every interval for every patient [4][1].
  • Systemic Scans: If your team is tracking systemic sites (like liver or bone), they may order specific body scans. A 68Ga-DOTATATE PET/CT may be used in specific contexts (like checking for PRRT suitability), but it is not triggered solely by any hormone rise, nor is it appropriate for every patient [5][6].

Biochemical Monitoring

Your blood work can act as an “early warning system” for functional (hormone-secreting) tumors. A rise in levels—such as ACTH, prolactin, or IGF-1 (often a more useful biochemical marker than GH, which is pulsatile)—can indicate tumor activity [5][7]. In some cases, rising hormone levels have prompted doctors to find new metastatic lesions [5][8]. However, hormone markers require subtype-specific interpretation, and nonfunctioning tumors may progress without a hormone signal.

Understanding Prognosis

Discussing prognosis for such a rare disease is difficult. You may encounter survival figures online, but these statistics often combine non-comparable datasets from different eras, with different referral bases and varying definitions.

  • Interpreting the Data: Some literature cites a median survival of about 1.5 years after metastases were first discovered [9]. Other registry data shows a 5-year survival rate of approximately 80%, though this drops to about 52% among patients with invasive primary behavior [10].
  • The Impact of Treatment Response: Your individual response to therapy is paramount. Some patients who respond well to TMZ (an effect seen in about 47% of treated patients in some reviews) achieve longer periods of stable disease [11][12]. Some patients have achieved long-term disease control lasting five years or more [13][14].
  • Context: These figures cannot predict an individual patient’s outcome [15][13]. A specialist should help interpret your prognosis based on your disease burden, pace of progression, and overall health.

Coping with “Scanxiety” and Supportive Care

The cycle of regular imaging and waiting for results—often called scanxiety—is a significant psychological burden [16]. It is common to feel increased distress leading up to a scan [16][17].

Practical Strategies for Coping

  • Mindfulness and Relaxation: Techniques like Mindfulness-Based Stress Reduction (MBSR) have been shown to help reduce the fear of recurrence [18][19].
  • Focus on the Present: Some patients find that “present-focused coping” helps manage the emotional toll [20].
  • Minimize the Wait: Talk to your team about a results plan. Knowing exactly when and how you will receive your results can help reduce uncertainty [17][21].
  • Build a Support Network: Connecting with others can provide emotional validation [17][22].

Remember that supportive and palliative care (including fatigue and pain management, rehabilitation, and optimizing endocrine replacement) should be available alongside tumor-directed treatment to support your quality of life [16].

Common questions in this guide

How often will I need scans for metastatic PitNET?
There is no single schedule for everyone with metastatic PitNET, also called pituitary carcinoma. Your team will set the timing and type of contrast-enhanced MRI or body imaging based on metastatic sites, symptoms, tumor receptor expression, and local protocol. A full brain-and-spine MRI or a 68Ga-DOTATATE PET/CT is not automatically needed at every interval.
Which hormone tests can show whether pituitary carcinoma is active?
Depending on the tumor subtype, clinicians may follow ACTH, prolactin, and IGF-1. IGF-1 can be more useful than growth hormone because growth hormone is released in pulses. Normal or unchanged hormone levels do not always rule out progression, especially in nonfunctioning tumors.
What do prognosis and survival statistics mean for me?
Published survival estimates for pituitary carcinoma vary because studies include different patients, treatments, and definitions. Your response to treatment such as temozolomide, tumor burden, rate of progression, and overall health are more relevant to an individualized outlook than any single statistic. Your specialist can help interpret the numbers.
How can I cope with anxiety before surveillance scans?
Scan-related anxiety is common when you are waiting for imaging and results. Mindfulness-based stress reduction, present-focused activities, a plan for when results will be shared, and support from trusted people may make the waiting period easier. An oncology psychologist or support group can provide additional help.
What supportive care can I receive while the tumor is being treated?
Supportive and palliative care can be provided alongside tumor-directed treatment for metastatic PitNET. It may include managing fatigue and pain, rehabilitation, and optimizing endocrine hormone replacement, with the goal of preserving quality of life. Ask your care team which services fit your needs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our specific plan for my surveillance imaging (MRI of brain and spine) and blood work over the next year?
  2. 2.Based on my response to temozolomide, what does the evidence suggest about my long-term prognosis?
  3. 3.Are there specific hormone levels, like ACTH or prolactin, that you will be monitoring to track if the tumor is active before it shows up on a scan?
  4. 4.Who should I call if I have questions about my scan results, and how quickly can I expect to hear back once the images are taken?
  5. 5.If my condition remains stable, when can we discuss potentially reducing the frequency of my scans to help manage my anxiety?
  6. 6.Can you refer me to an oncology psychologist or a support group for people living with rare, chronic cancers?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.

    Raverot G, Burman P, Abreu AP, et al.

    European journal of endocrinology 2025; (192(6)):R45-R78 doi:10.1093/ejendo/lvaf100.

    PMID: 40506054
  2. 2

    Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

    Yoo F, Kuan EC, Heaney AP, et al.

    Pituitary 2018; (21(3)):290-301 doi:10.1007/s11102-018-0872-8.

    PMID: 29404894
  3. 3

    How often should we perform magnetic resonance imaging (MRI) for the follow-up of pituitary adenoma?

    Constantinescu SM, Duprez T, Bonneville JF, Maiter D

    Annales d'endocrinologie 2024; (85(4)):300-307 doi:10.1016/j.ando.2024.03.004.

    PMID: 38604408
  4. 4

    Imaging and clinical course of metastatic pituitary neuroendocrine tumors (PitNET): A single center case series.

    Dagher SA, Alizada S, Al Qudah H, et al.

    The neuroradiology journal 2026; (39(2)):222-230 doi:10.1177/19714009251356278.

    PMID: 40576016
  5. 5

    Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease.

    Joehlin-Price AS, Hardesty DA, Arnold CA, et al.

    Diagnostic pathology 2017; (12(1)):34 doi:10.1186/s13000-017-0624-5.

    PMID: 28420444
  6. 6

    A Rare Case of Pituitary Carcinoma With Bone Metastases: 68Ga-DOTATATE PET/CT Findings.

    Filizoglu N, Ozguven S

    Clinical nuclear medicine 2022; (47(3)):e298-e299 doi:10.1097/RLU.0000000000004029.

    PMID: 35025796
  7. 7

    Prolactin-Secreting Pituitary Carcinoma with Dural Metastasis: Diagnosis, Treatment, and Future Directions.

    Seltzer J, Carmichael JD, Commins D, et al.

    World neurosurgery 2016; (91()):676.e23-8.

    PMID: 27157283
  8. 8

    Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case.

    Gamboa NT, Wilkerson C, Kundu B, et al.

    Journal of neurosurgery. Case lessons 2023; (5(3)).

    PMID: 36647250
  9. 9

    Metastatic pituitary tumors: an institutional case series.

    Yearley AG, Chalif EJ, Gupta S, et al.

    Pituitary 2023; (26(5)):561-572 doi:10.1007/s11102-023-01341-4.

    PMID: 37523025
  10. 10

    A Population-Level Analysis of Pituitary Carcinoma from the National Cancer Database.

    Carey RM, Kuan EC, Workman AD, et al.

    Journal of neurological surgery. Part B, Skull base 2020; (81(2)):180-186 doi:10.1055/s-0039-1683435.

    PMID: 32206537
  11. 11

    European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

    Raverot G, Burman P, McCormack A, et al.

    European journal of endocrinology 2018; (178(1)):G1-G24.

    PMID: 29046323
  12. 12

    Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.

    Losa M, Bogazzi F, Cannavo S, et al.

    Journal of neuro-oncology 2016; (126(3)):519-25 doi:10.1007/s11060-015-1991-y.

    PMID: 26614517
  13. 13

    Role of Surgery in the Multimodal Treatment of Pituitary Carcinoma: A Retrospective Single-Institution Case Series.

    Faraj CA, Tran M, Ferguson SD, et al.

    Cancers 2026; (18(13)) doi:10.3390/cancers18132064.

    PMID: 42449609
  14. 14

    Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.

    Bruno OD, Juárez-Allen L, Christiansen SB, et al.

    International journal of endocrinology 2015; (2015()):587893 doi:10.1155/2015/587893.

    PMID: 26106414
  15. 15

    Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review.

    Raymond P, Raverot G, Ilie MD

    Endocrine-related cancer 2023; (30(5)).

    PMID: 36852675
  16. 16

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  17. 17

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  18. 18

    Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial.

    Lengacher CA, Reich RR, Paterson CL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(24)):2827-34 doi:10.1200/JCO.2015.65.7874.

    PMID: 27247219
  19. 19

    How do mindfulness-based interventions promote coping and self-efficacy in patients with cancer: A systematic review of qualitative and quantitative data.

    Heinen JM, Laing EM, Schäffeler N, et al.

    Psycho-oncology 2024; (33(5)):e6350 doi:10.1002/pon.6350.

    PMID: 38777617
  20. 20

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  21. 21

    "You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

    Derry-Vick H, Prigerson HG, Hahne J, et al.

    Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

    PMID: 41338711
  22. 22

    Social isolation, coping efficacy, and social well-being over time in patients with lung cancer.

    Dunsmore VJ, Neupert SD

    Journal of behavioral medicine 2024; (47(5)):927-934 doi:10.1007/s10865-024-00508-z.

    PMID: 39078571

This page is for informational purposes only and does not constitute medical advice. Your endocrinology and oncology team can tailor surveillance, treatment, and emotional support to your specific situation.

Get notified when new evidence is published on Pituitary carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.